Clinical effect of immunochemotherapy for a patient with advanced gallbladder cancer: Report of a case

Surgery Today

Volumn 28, Issue 9, 1998, Pages 923-928

  Murakami, Koichi ^a   Tanimura, Hiroshi ^a   Yamaue, Hiroki ^a   Mizobata, Shizuma ^a   Noguchi, Kohei ^a   Nakamori, Mikihito ^a   Shimamoto, Tetsuya ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adoptive immunotherapy; Advanced gallbladder cancer; Chemotherapy; Cytotoxic T lymphocytes; Tumor infiltrating lymphocytes

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOMATOUS PERITONITIS; CASE REPORT; CYTOTOXIC T LYMPHOCYTE; FATALITY; FEMALE; GALLBLADDER CANCER; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; LYMPH NODE METASTASIS; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; GALLBLADDER; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031661824     PISSN: 09411291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005950050253     Document Type: Article

References (19)

1. Henson DE, Albores-Saavedra J, Corle D (1992) Carcinoma of the gallbladder, histologic types, stage of disease, grade, and survival rates. Cancer 70:1493-1497
2. Shich CJ, Dunn E, Standard JE (1981) Primary carcinoma of the gallbladder: a review of a 16-year experience at the Waterbury hospital health center. Cancer 47:996-1004
3. Rosenberg SA, Sepiess P, Latreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 223:1318-1321
4. Rosenberg SA, Packar BS, Aebersold PM, Solomon D, Topalin SL, Toy ST, Simon P, Lotze MT, Yang JG, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1617-1680
5. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival. J Immunol Methods 65:55-63
6. Yamaue H, Tanimura H, Noguchi K, Iwahashi M, Tsunoda T, Tani M, Tamai M, Hotta T, Mizobata S, Arii K (1991) Cisplatin treatment renders tumor cells more susceptible to attack by lymphokine-activated killer cells. J Clin Lab Immunol 35:165-170
7. Noguchi K, Tanimura H, Yamaue H, Iwahashi M, Tsunoda T, Tani M, Tamai M, Hotta T, Mizobata S, Arii K (1997) Enhancement of tumor cell susceptibility to tumor-infiltrating lymphocytes by treatment with Cisplatin. J Cancer Res Clin Oncol 123:345-351
8. Yamaue H, Tanimura H, Tsunoda T, Tani M, Iwahashi M, Noguchi K, Tamai M, Hotta T, Arii, K (1991) Chemosensitivity testing with highly purified fresh human tumor cells with the MTT colorimetric assay. Eur J Cancer 27:1258-1263
9. Yamaue H, Tanimura H, Noguchi K, Hotta T, Tani M, Tsunoda T, Iwahashi M, Tamai M, Iwakura S (1992) Chemosensitivity testing of fresh human gastric cancer with highly purified tumor cells using MTT assay. Br J Cancer 66:794-799
10. Yamaue H, Tanimura H, Tsunoda T, Iwahashi M, Noguchi K, Tani M, Tamai M, Inoue M (1990) Functional and phenotypic analyses of interleukin 2-activated tumor-infiltrating lymphocytes. Biotherapy 2:247-259
11. Tani M, Tanimura H, Yamaue H, Mizobata S, Iwahashi M, Tsunoda T, Noguchi K, Tamai M, Hotta T, Terasawa H, Arii K (1995) Generation of CD4 cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients. Int J Cancer 60:802-805
12. Scheithauer W, Clark GM, Salmon SE, Dorda W, Shoemaker PH, Von Hoff DD (1986) Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep 70:1379-1382
13. Falkson G, MacIntyre JM, Moertel G (1984) Eastern cooperative oncology experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 15:965-969
14. Tsunoda T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Tamai K, Arii K, Noguchi K (1992) The promotive effect of interleukin 4 with interleukin 2 in the proliferation of tumor-infiltrating lymphocytes from patients with malignant tumor. Biotherapy 4: 9-15
15. Hosokawa M, Sawamura Y, Morikage T, Okada F, Xu ZY, Morikawa K, Itoh K, Kobayashi H (1988) Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide. Cancer Immunol Immunother 26:250-256
16. Eastman A, Schulte N (1988) Enhanced DNA repair as a mechanism of resistance to cis-diammine-dichloroplatinum (II). Biochemistry 27:4730-4734
17. Mizutani Y, Bonavida B, Nio Y, Yoshida O (1993) Enhanced susceptibility of cis-diammine-dichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Cancer 71:1313-1321
18. Collins JL, Kao MS (1989) The anticancer drug, cisplatin, increases the naturally occurring cell-mediated lysis of tumor cells. Cancer Immunol Immunother 29:17-22
19. Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, Takahashi T (1991) Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 51:1934-1939